Lonza’s 2024 Earnings Report Released

The Swiss biotechnology company Lonza recently released its 2024 earnings report, showcasing an income of 6.6 billion Swiss francs, equivalent to around $7.2 billion USD. This financial success was underpinned by a 7 percent growth in adjusted underlying sales for the year. However, the total sales did not fully align with this figure due to a decline in the sales of the COVID-19 MRNA vaccine.

Lonza’s commitment to future growth was evident through its investment of CHF 1.4 billion in 2024, representing 22% of its sales revenue. This investment was part of Lonza’s ongoing organic investment program to foster growth across various technologies. One of the significant milestones for Lonza in 2024 was the acquisition of the Genentech facility in Vacaville from Roche. Strong order volumes throughout the year were also highlighted as a key driver of success for the company.

Among Lonza’s divisions, the Small Molecules segment saw an impressive sales growth of 9.3 percent, while the Cell & Gene division reported a more modest 1.1 percent growth. In contrast, the Capsules & Health Ingredients division experienced a 6.6 percent decline in sales. As a result, Lonza announced its decision to exit this sector in 2025.

Lonza’s CEO, Wolfgang Weinand, expressed optimism about the company’s performance in 2024, emphasizing the commercial progress demonstrated by its CDMO businesses. High contract signings across various technologies reflected the positive momentum within the organization. Looking ahead to 2025 and beyond, Lonza is focusing on implementing its One Lonza strategy, which involves a streamlined organizational structure and a renewed emphasis on third-party pharmaceutical manufacturing.

The One Lonza program aims to consolidate Lonza’s operations and enhance the customer experience across its service offerings. By divesting from the Capsules & Health Ingredients sector, Lonza seeks to position itself for future growth and better serve its global customer base. Weinand articulated the company’s commitment to realizing the vision of One Lonza, highlighting the collaborative efforts of the global team in driving this transformation.

Lonza’s 2024 earnings report signifies a year of growth and strategic realignment for the company. With a strong financial performance, significant acquisitions, and a clear strategic direction moving forward, Lonza is poised to capitalize on opportunities in the biotechnology sector and drive sustainable growth in the years to come.